Literature DB >> 35342504

Fluorescence in the Sclera, Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections.

Emel Öztürk Durmaz1, Deniz Demircioğlu1.   

Abstract

Favipiravir, an antiviral agent originally used for influenza infections, has become popular due to its beneficial signals in coronavirus disease. It is currently used in some countries within COVID-19 treatment protocols. This is an initial report of favipiravir-related fluorescence observed in three healthcare providers working in the same ward in our hospital. All three individuals had been diagnosed with COVID-19 two months earlier and were treated with favipiravir. None of the three individuals received hydroxychloroquine or tetracyclines. Wood's light examination led to an incidental discovery of favipiravir-induced fluorescence involving the sclera, nails, and teeth. In all patients, white linear, square, and band-like specks of fluorescence were noticed on the sclera of both eyes, some teeth, and the proximal part of all fingernails and toenails. Exposure of the eyes to the Wood's light was for a brief duration of 3 to 5 seconds during examination and photodocumentation. Favipiravir might cause bright white fluorescence of nails, sclera, and teeth, detectable by Wood's light even two months after its cessation.
Copyright © 2022. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  COVID-19; Favipiravir; UV lamp; Wood’s light; conjunctiva; coronavirus; fluorescence; nail; polyvinylpyrrolidone; teeth

Year:  2022        PMID: 35342504      PMCID: PMC8944284     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  10 in total

1.  Fluorescence of nails from quinacrine hydrochloride.

Authors:  R R KIERLAND; C SHEARD
Journal:  J Am Med Assoc       Date:  1946-07-06

2.  Tetracycline induced green conjunctival pigment deposits.

Authors:  V L Morrison; D O Kikkawa; B G Herndier
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  Wood's lamp.

Authors:  L K Gupta; M K Singhi
Journal:  Indian J Dermatol Venereol Leprol       Date:  2004 Mar-Apr       Impact factor: 2.545

4.  Doxycycline-induced staining of permanent adult dentition.

Authors:  E Ayaslioglu; E Erkek; A A Oba; E Cebecioğlu
Journal:  Aust Dent J       Date:  2005-12       Impact factor: 2.291

5.  COVID-19 and nail manifestation: be on the lookout for the red half-moon nail sign.

Authors:  Silvia Méndez-Flores; Angela Zaladonis; Rodrigo Valdes-Rodriguez
Journal:  Int J Dermatol       Date:  2020-08-29       Impact factor: 2.736

6.  Strong fluorescence of poly(N-vinylpyrrolidone) and its oxidized hydrolyzate.

Authors:  Guoshan Song; Yannan Lin; Zhongcheng Zhu; Heying Zheng; Jinping Qiao; Changcheng He; Huiliang Wang
Journal:  Macromol Rapid Commun       Date:  2014-11-25       Impact factor: 5.734

7.  The red half-moon nail sign: a novel manifestation of coronavirus infection.

Authors:  I Neri; A Guglielmo; A Virdi; V Gaspari; M Starace; B M Piraccini
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-13       Impact factor: 6.166

Review 8.  Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.

Authors:  Antonio Martinez-Lopez; Carlos Cuenca-Barrales; Trinidad Montero-Vilchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Am Acad Dermatol       Date:  2020-08-07       Impact factor: 11.527

9.  Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L.

Authors:  Michael Dominic Sacco; Chunlong Ma; Panagiotis Lagarias; Ang Gao; Julia Alma Townsend; Xiangzhi Meng; Peter Dube; Xiujun Zhang; Yanmei Hu; Naoya Kitamura; Brett Hurst; Bart Tarbet; Michael Thomas Marty; Antonios Kolocouris; Yan Xiang; Yu Chen; Jun Wang
Journal:  Sci Adv       Date:  2020-12-09       Impact factor: 14.136

Review 10.  Favipiravir use for SARS CoV-2 infection.

Authors:  Alberto Boretti
Journal:  Pharmacol Rep       Date:  2020-10-27       Impact factor: 3.024

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.